



Review: Mechanisms of methotrexate induced small intestinal injury and its prevention- an update

Dr. Premila Abraham* and Dr. Muthuraman N

Department of Biochemistry,
Christian Medical College,
Bagayam, Vellore.632002
*Corresponding Author

Received 27 June, 2024; Revised 04 July, 2024; Accepted 06 July, 2024 © The author(s) 2024.
Published with open access at www.questjournals.org

I. MTX uses

Methotrexate (MTX), a structural analogue of folic acid, is one of the most widely used therapeutic agents available to treat many solid tumors, hematologic malignancies, and autoimmune diseases [1,2]. It is currently the most common anti-rheumatic drugs prescribed for the treatment of rheumatoid arthritis and other rheumatic disorders [3]. MTX earned a new indication with its efficacy in the treatment for refractory inflammatory bowel disease [4]. Patients suffering from psoriasis have benefited from MTX in addition to those with atopic dermatitis, chronic urticarial infection [5].

Methotrexate is administered at doses that range from 12 mg intrathecally and 20 mg/m² orally, intramuscularly, or intravenously as weekly maintenance chemotherapy for acute lymphocytic leukemia (ALL) to doses as high as 33,000 mg/m² intravenously for some other indications [6]. Doses of 500 mg/m² or higher given intravenously are defined as high-dose methotrexate (HDMTX) and are used to treat a variety of adult and pediatric cancers, including ALL, osteosarcoma, and lymphomas [7-9].

II. Gastrointestinal side effects of MTX

In addition to cancer cells being affected by MTX, rapid proliferating cells such as bone marrow and gastrointestinal cells are also affected. Adverse reactions from long-term low-dose MTX treatment may be present in 30% to 80% of patients, and acute toxicity in patients taking MTX at low doses may, in some cases, be life-threatening [10]. HDMTX therapy can cause significant toxicity, which not only leads to morbidity and occasional mortality but may also interrupt cancer treatment, potentially leading to inferior anticancer outcomes. Its cytotoxic structure causes life-threatening side effects, such as intestinal injury, and as a result of this, use of this agent is often limited. Gastrointestinal toxicity is one of the most frequently observed side effects that may lead to a reduction in the dose or even a discontinuation of the drug [11,12].

Chemotherapy induced mucositis is a debilitating, dose-limiting, and costly side effect of cancer therapy. Mucositis occurs in 40% of cancer patients after standard doses of treatment and in almost 100% of patients treated with high doses of chemotherapy [13] and can affect the entire gastrointestinal tract causing discomfort, nausea, vomiting, bloating, diarrhoea, ulceration, bleeding and in some cases result in septicaemia [14]. It leads to dose reduction or prevention of continuation of selected therapies, prolongs hospital stay, increases re-admission rates, increases healthcare cost, compromises patients' nutritional status, impairs patients' quality of life, and is occasionally fatal. Generally, methotrexate-induced gastrointestinal mucositis is a moderately severe but common side effect in routine clinical use [15]. The small intestinal damage (enteritis) induced by MTX treatment results in malabsorption and diarrhea [16,17]. Approximately 60% of cancer patients that receive a chemotherapy treatment that includes MTX experience diarrhea and malabsorption [18]. This malabsorption results in weight loss and disturbs the cancer chemotherapy of patients.

III. Mechanisms of methotrexate induced intestinal injury

The exact mechanism of intestinal toxicity caused by MTX is not fully understood. However, it is reported that MTX could cause intestinal damage via producing reactive oxygen species (ROS), reactive nitrogen species (RNS) and activation of NF- κ B [19,20]. NF- κ B regulates the production of numerous cytokines and mediates cell damage, which can be activated by ROS generation [21,22]. The production of inflammatory cytokines such as TNF- α , IL-1 β , and IL-6 is provoked by ROS production [23]. Also, MTX administration leads to inflammatory cascades involving the activation of NF- κ B, with increased expression of pro-inflammatory cytokines such as IL-6 and TNF- α , followed by activation of the JAK/STAT3 signaling [24,25]. Upon JAK/STAT phosphorylation, it translocates to the nucleus, binds with the target gene promoter region, and provokes the transcription of genes involved in the inflammatory reactions [26]

3.1. Role of oxido-nitrosative stress and mitochondrial damage in MTX induced small intestinal injury

Several studies have shown that reactive oxygen species, reactive nitrogen species, nitro-oxidative stress [27-36], mitochondrial damage [37-39] and epithelial cell apoptosis play important roles in MTX induced small intestinal injury in animal models [40-46]. When intestinal damage is triggered by MTX, increased ROS production and depletion of antioxidant defense mechanism plays a crucial role [47]. ROS mediates lipid peroxidation, which leads to tissue damage development after MTX administration. This degradation of cell membranes impairs normal cellular activities [48]. The antioxidant glutathione (GSH) content in cells was lowered and cytosolic peroxide was elevated following MTX treatment [49]. Multiple previous studies showed that MTX treatment altered redox status in the small intestine and increased intestinal ROS biomarkers such as malondialdehyde [50-52]. The direct toxic effects of MTX are thought to be caused by excessive generation of free radicals, causing an imbalance between free radical production and antioxidant defense, which finally results in the development of oxidative stress [48,53].

Oxidative stress causes necroptosis and apoptosis in enterocytes, as well as the destruction of the intestinal structure [54,55]. In addition, cytoskeletal proteins and other cellular proteins are damaged by excess of free radicals in the intestinal epithelium. Furthermore, it increases intestinal permeability, which makes it more likely for microorganisms and antigens from the luminal environment to enter the bloodstream and increase the risk of systemic reaction syndrome [56]

We have been working on the elucidation of the mechanism of MTX induced intestinal toxicity, using rat model, over the past 13 years. We have demonstrated that increased nitro-oxidative stress, peroxynitrite overproduction and protein tyrosine nitration, enterocyte apoptosis and necrosis, mitochondrial damage, upregulation of mitochondrial apoptotic pathway. We have shown that methotrexate administration induces differential and selective protein tyrosine nitration and cysteine nitrosylation in the subcellular organelles of the small intestinal mucosa of rats.

These are our significant findings

1. Methotrexate administration causes increased apoptosis and necrosis of epithelial cells and marked neutrophil infiltration as evidenced by four fold increase in myeloperoxidase (MPO) activity in the small intestines of rats. Activation of the mitochondrial apoptotic pathway contributes to methotrexate-induced small intestinal injury in rats [57]

2. Alteration in antioxidant defense mechanisms in the small intestines of methotrexate treated rat may contribute to its gastrointestinal toxicity

Tissue reduced glutathione, protein thiol and the activities of glutathione reductase, superoxide dismutase and catalase were significantly decreased in the intestines of MTX treated rats as compared with controls. Nitrotyrosine, measured immunohistochemically was detected in all the parts of the small intestine. On the other hand the activities of glutathione peroxidase, glutathione S transferase, protein carbonyl content, malondialdehyde, and conjugated dienes were significantly increased in the intestines of MTX treated rats. The results of the study suggest that alteration in antioxidant enzymes may contribute to enhanced oxidative stress in the intestines of MTX treated rats and hence small intestinal damage. [58]

3. Increased nitrosative stress may play a critical role in MTX induced small intestinal injury

Inducible nitric oxide synthase expression was increased in the small intestines of MTX treated rats. Nitrotyrosine, the foot print of peroxynitrite production measured immunohistochemically was detected in all the parts of the small intestine. Duodenum stained the most for nitrotyrosine, followed by ileum and then jejunum. These findings reveal that iNOS induction and peroxynitrite overproduction -nitrosative stress may play a critical role in methotrexate induced small intestinal damage [59]

4. Methotrexate administration induces differential and selective protein tyrosine nitration and cysteine nitrosylation in the subcellular organelles of the small intestinal mucosa of rats

Tyrosine nitrated proteins and cysteine nitrosylated proteins were determined in the subcellular organelles fractions of mucosa using immunoprecipitation and western blot. The proteins in the subcellular fractions were separated by 1D electrophoresis, and probed with anti -nitrotyrosine antibody and anti-nitrosocysteine antibody. After MTX treatment, a general increase in protein tyrosine nitration as well as a change in the spectrum of proteins that underwent nitration was observed. The relative densities of the 3 nitrotyrosine protein adducts were as follows: Mitochondria > cytosol > microsomes > nucleus. In the mitochondrial fraction increased nitration of 12 kDa, 25 kDa, 29 kDa, 47 kDa, and 62 kDa proteins, in the cytosol increased nitration of 12 kDa, 19 kDa, 45 kDa, and 60 kDa proteins and in the nuclear fraction increased nitration of 17 kDa, 35 kDa, and 58 kDa proteins was observed. On the other hand, MTX treatment resulted to a general decrease in protein cysteine nitrosylation in all the subcellular fractions. These results suggest that MTX induced, PON mediated small intestinal injury is mediated by differential nitration and nitrosylation of proteins in the subcellular organelles with increased protein tyrosine nitration and decreased cysteine nitrosylation [60]

6. Mitochondrial dysfunction and respiratory chain defects in a rodent model of methotrexate-induced enteritis
Respiratory control ratio, the single most useful and reliable test of mitochondrial function, and 3-(4,5-dimethylthiazol-2-yl)-2,5-diphenyltetrazolium bromide reduction, a measure of cell viability were significantly reduced in all the fractions of MTX-treated rat enterocytes. A massive decrease (nearly 70%) in the activities of complexes II and IV was also observed. The results of the present study suggest that MTX-induced damage to enterocyte mitochondria may play a critical role in enteritis [61].

7. Melatonin pretreatment protected against methotrexate-induced small intestinal damage in rats. The protective effect is mediated by attenuation of oxido- nitrosative stress, protein tyrosine nitration, and PARP activation [62].

3.2. Nuclear factor erythroid-2-related factor 2 (Nrf2)-Kelch-like ECH-associated protein 1 (Keap1) pathway and intestinal injury by MTX

The primary regulator of cellular responses to external stressors is nuclear factor erythroid-2-related factor 2 (Nrf2) [63]. The nuclear factor erythroid-2-related factor 2 gene is responsible for encoding antioxidants and detoxification enzymes providing a redox sensing system [64]. Previous studies have reported the involvement of Nrf2 in MTX-induced intestinal injury [65].

3.3 Role of inflammation in MTX-induced intestinal injury

Three main alterations take place during acute inflammation. 1. increased capillary permeability, which permits larger serum molecules to enter the tissues. 2. increased leukocyte migration into the tissue and 3. increased blood flow to the affected area [66]. NF- κ B is a key regulator of inflammation that is involved in the synthesis of inflammatory mediators and activation of pro-inflammatory cytokines [67]. NF- κ B regulates the expression of numerous immune system components and modulates inflammation [68]. Among these are pro-inflammatory cytokines, chemokines, and inducible enzymes such as nitric oxide synthase (iNOS) and cyclooxygenase-2 (COX-2). Moreover, NF- κ B regulates cytokines including IL-2 and IL-12 that affect the proliferation and differentiation of lymphocytes. It is also currently believed that pro-inflammatory cytokines, such as tumor necrosis factor alpha (TNF- α), interleukin-1 beta (IL-1 β), and interleukin-6, may also play a role in MTX-induced intestinal damage [69,70].

We have demonstrated that PARP overactivation and activation of NF- κ B-iNOS-COX2-TNF α inflammatory signaling pathway play important role in MTX induced small intestinal injury. MTX treatment resulted in NF κ B activation and nuclear translocation as evidenced by immunofluorescence, immunohistochemistry, and western blot. NF κ B mRNA expression was also increased. There was increased protein and mRNA expressions of NF κ B target genes, TNF- α , iNOS, COX-2, PLA2, HO-1, HSP70, MMPs 2 and Aminoguanidine pretreatment attenuated MTX induced activation of NF κ B and its proinflammatory target genes and improved MTX induced morphological changes [61b,62b].

3.4. Role of JAK/STAT3/SOCS3 in MTX-induced small intestinal injury

JAK/STAT is the signalling pathway for many cytokines and growth factor production. When cytokines such as IL-6 bind to JAK/STAT3, STAT3 becomes phosphorylated. After nuclear translocation, the phosphorylated form of STAT3 acts as a transcriptional factor that upregulates the genes related to inflammation [71,72]. Studies have shown that MTX administration provoked JAK1 and STAT3 phosphorylation in rat models of intestinal injury.

The regulation of the JAK/STAT system involves numerous mechanisms, one of which is the control of JAK kinase activity phosphorylation by suppressor of cytokine signaling (SOCS) proteins [73]. The most

important member of the SOCS family is SOCS3, which can block JAK/STAT3 signaling in response to mitosis, growth factors, and cytokines. SOCS3 has ability to reduce JAK phosphorylation by inhibiting JAK kinase binding and competing with JAK to prevent STAT3 phosphorylation [74]. Previous study showed that MTX administration resulted in decline in SOCS3 level [75].

3.5. Involvement of peroxisome proliferator-activated receptor-gamma (PPAR- γ) in MTX-induced intestinal toxicity

It is widely known that PPAR- γ is a powerful inhibitor of ROS and inflammation. Its conformation changes upon activation preventing the production of pro-inflammatory mediators, which in turn prevents a range of inflammatory responses [76]. The reduction of NF- κ B, STAT1, and AP-1 transcriptional activity is one of the PPAR- γ mediated anti-inflammatory actions [77]. The decreased level of PPAR- γ is associated with increased oxidative stress in a rat model of duodenal injury induced by MTX [78,79].

Although several attempts have been made to investigate the mechanism of methotrexate induced gastrointestinal toxicity, the underlying biological events contributing to the pathogenesis of mucositis are still being defined and multiple pathways leading to epithelial cell death seem likely.

IV. Therapeutic protection against methotrexate-induced intestinal injury

Several natural and synthetic compounds have been tried to attenuate MTX induced small intestinal mucositis as discussed below

Aminoguanidine

Aminoguanidine (AG) is an inducible nitric oxide synthase (iNOS) inhibitor, which can regulate the activity and expression levels of iNOS [80]. Leitao et al have demonstrated that inhibition of iNOS by aminoguanidine prevents MTX induced small intestinal injury in rats [81]. We have demonstrated that pretreatment with aminoguanidine had a dose-dependent protective effect on MTX-induced mucositis. AG pretreatment reduced iNOS protein levels, mucosal nitric oxide levels, and protein tyrosine nitration. AG pretreatment also restored the activities of electron transport chain (ETC) complexes, vital tricarboxylic acid (TCA cycle) enzymes, and mitochondrial antioxidant enzymes [61b].

Melatonin

More commonly known as the sleep hormone, melatonin also has antioxidant, anti-inflammatory, antiapoptotic, and many other crucial properties [82,83]. Melatonin, a pineal hormone functions as a high-capacity antioxidant, or free radical scavenger, within mitochondria, playing a dual role in combating cellular oxidative stress. Firstly, it directly neutralizes free radicals, and secondly, it promotes the gene expression of essential antioxidant enzymes, such as superoxide dismutase, glutathione peroxidase, glutathione reductase, and catalase. The direct antioxidant and free radical scavenging properties of melatonin are mainly due to its electron-rich aromatic indole ring, which makes it a potent electron donor that can significantly reduce oxidative stress [83,84]. We have shown that melatonin protects against methotrexate-induced small intestinal damage. Its effect is mediated by attenuation of oxido-nitrosative stress, protein tyrosine nitration, and PARP activation [62,85a,b].

Natural compounds

Many natural compounds have been tried to ameliorate MTX mucositis in animal models.

Rutin

Rutin is one of the main flavonoid glycosides present in fruits and fruit peels, mainly in citrus fruits such as lemons and oranges [86]. It possesses several pharmacological activities, including the ability to effectively scavenge superoxide radicals and act as an immunomodulator, anti-inflammatory, antioxidant, and anti-carcinogenic [87,88]. The mechanism of action of rutin is due to its antioxidant capacity through the Nrf2/ARE and anti-inflammatory properties due to NF- κ B, COX-2, IL-6, and TNF- α suppression. Studies have shown that rutin is able to attenuate intestinal oxidative stress changes by lowering intestinal MDA and elevating GSH content and restoring SOD activity. Rutin attenuated MTX-induced intestinal inflammation, as proved by decreased IL-2 and increased IL-4 and IL-10. In addition, rutin was found to inhibit the enzymatic activity of COX and lipoxygenase. Thus rutin, has protective effect against MTX-induced intestinal injury [89].

Hesperidin

Hesperidin is a flavanone group member, [90]. Citrus fruits, including lemon, orange, and grapefruit, are a good source of this natural antioxidant compound [91,92]. It exhibited antiapoptotic, anti-inflammatory, and anti-carcinogenic properties together with its antioxidant activity [93-95]. Pretreatment with hesperidin before

MTX administration attenuated intestinal injuries by decreasing oxidative stress and myeloperoxidase activity. It also inhibited iNOS activity and reduced IL8 levels [96].

Lycopene

Tomatoes and other red fruits have a high concentration of the red pigment lycopene. Lycopene has the ability to scavenge ROS [97,98] and has anti-inflammatory properties [99]. Lycopene protects against MTX induced intestinal injury by decreasing the levels of IL-1 β , and oxidative stress [100].

Quercetin

Of all the flavonoids, quercetin is the most widely distributed. Apples, potatoes, soybeans, and other fruits and vegetables are rich sources of quercetin [101]. Quercetin is a powerful antioxidant that protects against ROS and has been shown to reduce MTX induced mucosal injury in rats [102].

Apocynin

Apocynin (APO) is a natural organic methoxy-substituted catechol compound that acts as an antioxidant. [103]. APO reduced intestinal oxidative stress by decreasing intestinal MDA and increasing SOD activity and GSH content in MTX treated rats. APO exhibited powerful anti-inflammatory by inhibiting the production of NF- κ B mRNA and decreasing pro-inflammatory cytokine levels together with upregulating anti-inflammatory PPAR- γ proteins [104].

Taurine

Numerous studies have proved that taurine has antioxidant and anti-inflammatory properties. Previous studies have demonstrated the protective effect of taurine against MTX-induced intestinal injury through a variety of mechanisms including modulation of Keap1/Nrf2/HO-1 signals, inhibition of the NF- κ B/iNOS signal and reduction of caspase 3 expression [105].

Omega-3 polyunsaturated fatty acids

Omega-3 fatty acids have anti-inflammatory and antioxidant properties [106,107]. Omega-3 polyunsaturated fatty acids (PUFAs) exhibited potential protective effect against MTX-induced apoptosis in intestinal mucosa [108]. Rats treated with MTX and omega-3 PUFA- showed a significant decrease in enterocyte apoptosis together with reduced numbers of macrophages in conjunction with lower levels of COX-2, TNF- α , and NF- κ B in the mucosa of treated rats [108].

Umbelliferone

A naturally occurring member of the coumarin family, umbelliferone (UMB) or 7-hydroxycoumarin, is present in a wide variety of plants, including garden angelica, coriander, and carrots [109]. Numerous investigations have determined that UMB possesses biological properties, including anti-inflammatory [110], antioxidant [111,112] and anticancer effects [113]. Studies have shown that UMB protects against MTX induced intestinal damage by inhibiting oxidative stress, as shown by decrease in MDA contents and the elevation of Nrf2, SOD, HO-1, and GSH levels. Additionally, it inhibited STAT3, NF- κ B, IL-6, and TNF- α levels, thereby exhibiting anti-inflammatory effects.

Other compounds

Compounds including salean, carnitine, β glucan, N acetylcysteine, β carotene, proanthocyanidine, ozone, ginger, lycopene, turmeric, resveratrol, arginine, and vitamin E have been shown to protect against MTX induced small intestinal injury in animals [114-118].

V. Conclusions

Despite its longstanding recognition, frequency, and clinical impact, treatment options for MTX induced intestinal mucositis are not satisfactory. Many natural and synthetic compounds have been tried to ameliorate MTX mucositis in animal models. But none of them offer complete, mechanism based protection. Therefore, there are no FDA approved drugs for the treatment of intestinal mucositis. The management of intestinal mucositis largely involves the control of symptoms using antibiotics, anaesthetics, and analgesics. Thus, there is an urgent need to develop drugs that minimise GI toxicity.

References

- [1]. Schmiegelow K, Nielsen SN, Frandsen TL, Nersting J. Mercaptopurine/Methotrexate maintenance therapy of childhood acute lymphoblastic leukemia: clinical facts and fiction. *J Pediatr Hematol Oncol.*2014; 36; 503-17.
- [2]. Abolmaali SS, Tamaddon AM, Dinarvand R. A review of therapeutic challenges and achievements of methotrexate delivery systems for treatment of cancer and rheumatoid arthritis. *Cancer ChemotherPharmacol.*2013; 71:1115-30 Review.
- [3]. Doan T, Massarotti E. Rheumatoid arthritis, an overview of new and emerging therapies. *J ClinPharmacol.* 2004; 45: 751-62.
- [4]. Xu P, He Y, Chen Y, Chao K, Chen B, Mao R, Tang R, Zhu Z, Zeng Z, Chen. M. [The efficacy and safety of methotrexate in refractory Crohn's disease]. *Zhonghua Nei Ke Za Zhi* 2014; 53:188-92. Chinese.
- [5]. Radhika A. S. , Crystal E. N , Allison L. L , Ravi R. P , Uyen Ngoc M , Stephen K. Tying. Brief Update on Dermatologic Uses of Methotrexate 2019 Nov;24(6):5-8
- [6]. Widemann BC, Adamson PC. Understanding and managing methotrexate nephrotoxicity. *The Oncologist.* 2006;11:694–703
- [7]. Stoller RG, Hande KR, Jacobs SA, et al. Use of plasma pharmacokinetics to predict and prevent methotrexate toxicity. *N Engl J Med.* 1977;297:630–634
- [8]. Mitchell MS, Wawro NW, DeConti RC, et al. Effectiveness of high-dose infusions of methotrexate followed by leucovorin in carcinoma of the head and neck. *Cancer Res.* 1968;28:1088–1094.
- [9]. Abrey LE, DeAngelis LM, Yahalom J. Long-term survival in primary CNS lymphoma. *J Clin Oncol.*1998;16:859–863
- [10]. Kivity S, Zafrir Y, Loebstein R, Pauzner R, Mouallem M, Mayan H. Clinical characteristics and risk factors for low dose methotrexate toxicity: a cohort of 28 patients. *Autoimmun Rev.* 2014;13:1109–13
- [11]. Kesik V, Uysal B, Kurt B, Kismet E, Koseoglu V. Ozone ameliorates methotrexate-induced intestinal injury in rats. *Cancer Biol Ther* 2009;8(17):1623–8. doi: 10.4161/cbt.8.17.9203
- [12]. Tsukada T, Nakano T, Miyata T, Sasaki S. Life-Threatening Gastrointestinal Mucosal Necrosis during Methotrexate Treatment for Rheumatoid Arthritis. *Case Rep Gastroenterol.*2013; 7:470-5
- [13]. Keefe DM, Brealey J, Goland GJ, Cummins AG. Chemotherapy for cancer causes apoptosis that precedes hypoplasia in crypts of the small intestine in humans. *Gut.* 2000;47:632–7.
- [14]. Sonis ST, Elting LS, Keefe DMK, Peterson DE, Schubert M, Hauer-Jensen M, et al. . Perspectives oncancer therapy-induced mucosal injury: pathogenesis, measurement, epidemiology, and consequences for patients. *Cancer.* 2004;100:1995–2025.
- [15]. Pinkerton CR, Cameron CH, Sloan JM, Glasgow JF, Gwevava NJ. Jejunal crypt cell abnormalities associated with methotrexate treatment in children with acute lymphoblastic leukaemia. *J. Clin. Pathol.*,1982;35:1272–1277
- [16]. Boscá MM, Anón R, Mayordomo E, Villagrana R, Balza N, Amorós C, Corts JR, Benages A. Methotrexate induced sprue-like syndrome. *World J Gastroenterol.* 2008; 14:7009-11
- [17]. Cudmore J, Seftel M, Sisler J, Zarychanski R. Methotrexate and trimethoprim-sulfamethoxazole: toxicity from this combination continues to occur. *Can Fam Physician.* 2014; 60:53-6.
- [18]. Sezer A, Usta U, Cicin I. The effect of *Saccharomyces boulardii* on reducing irinotecan-induced intestinal mucositis and diarrhea. *Med Oncol* 2009; 26: 350–357
- [19]. Miyazono Y, Gao F, Horie T (2004) Oxidative stress contributes to methotrexate-induced small intestinal toxicity in rats. *Scand J Gastroenterol* 39:1119–1127
- [20]. Natarajan K, Abraham P, Kota R, Isaac B. NF- κ B-iNOS-COX2-TNF α inflammatory signaling pathway plays an important role in methotrexate induced small intestinal injury in rats. *Food Chem Toxicol.* 2018 Aug;118:766-783
- [21]. Baeuerle PA, Baichwal VR (1997) NF- κ B as a frequent target for immunosuppressive and anti-inflammatory molecules. *Adv Immunol* 65:111–138
- [22]. Asehounne K, Strassheim D, Mitra S, Kim JY, Abraham E (2004) Involvement of reactive oxygen species in toll-like receptor 4-dependent activation of NF- κ B. *J Immunol* 172:2522–2529
- [23]. Asami J, Shimizu T (2021) Structural and functional understanding of the toll-like receptors. *Protein Sci* 30:761–772
- [24]. RFd AJ, da Silva Reinaldo M, GAdC B, PdF C, MAdM F (2014) Olmesartan decreased levels of IL-1b and TNF- α , down-regulated MMP-2, MMP-9, COX-2, RANK/RANKL and Up-Regulated SOCs-1 in an intestinal mucositis model. *PLoS ONE* 9:e114923
- [25]. Kamel MY, Ahmed SM, Abdelzaher WY, Welson NN, Abdel-Aziz AM (2022) Role of IL-6/STAT3 pathway in mediating the protective effect of agomelatine against methotrexate-induced lung/intestinal tissues damage in rats. *Immunopharmacol Immunotoxicol* 44:35–46
- [26]. Xin P, Xu X, Deng C, Liu S, Wang Y, Zhou X, Ma H, Wei D, Sun S (2020) The role of JAK/STAT signaling pathway and its inhibitors in diseases. *Int Immunopharmacol* 80:10
- [27]. Akacha A, Rebai T, Zourgui L, Amri M Preventive effect of ethanolic extract of cactus (*Opuntia ficusindica*) cladodes on methotrexate-induced oxidative damage of the small intestine in Wistar rats. *J Cancer Res Ther.* 2018 Sep;14(Supplement):S779-S784.
- [28]. Sklyarova Y, Fomenko I, Lozynska I, Lozynskiy A, Lesyk R, Sklyarov A. Hydrogen Sulfide Releasing 2-Mercaptoacrylic Acid-Based Derivative Possesses Cytoprotective Activity in a Small Intestine of Rats with Medication-Induced Enteropathy. *Sci Pharm.* 2017 Oct 24;85(4). pii: E35.
- [29]. Ozcicek A, Cetin N, Keskin Cimen F, Tumkaya L, Malkoc I, Gulaboglu M, Yarali O, Suleyman B. The Impact of Resveratrol on Oxidative Stress Induced by Methotrexate in Rat Ileum Tissue: Evaluation of Biochemical and Histopathological Features and Analysis of Gene Expression. *Med Princ Pract.*2016;25(2):181-6.
- [30]. Zhang B, Lu C, Bai M, He X, Tan Y, Bian Y, Xiao C, Zhang G, Lu A, Li S. Tetramethylpyrazine identified by a network pharmacology approach ameliorates methotrexate-induced oxidative organ injury. *J Ethnopharmacol.* 2015 Dec 4;175:638-47.
- [31]. Boybeyi Ö, Gunal YD, Atasoy P, Kısa U, Aslan MK. The effect of colchicine and low-dose methotrexate on intestinal ischemia/reperfusion injury in an experimental model. *J Pediatr Surg.* 2014 Oct;49(10):1471-4.
- [32]. Kaynar L, Cetin A, Hacıoğlu SK, Eser B, Koçyigit İ, Canöz Ö, Tasdemir A, Karadag C, Kurnaz F, Saraymen R, Silici S Efficacy of royal jelly on methotrexate-induced systemic oxidative stress and damage to small intestine in rats.. *Afr J Tradit Complement Altern Med.* 2012 Apr 2;9(3):412-7.
- [33]. Maeda T, Miyazono Y, Ito K, Hamada K, Sekine S, Horie T Oxidative stress and enhanced paracellular permeability in the small intestine of methotrexate-treated rats. *Cancer Chemother Pharmacol.* 2010 May;65(6):1117-23.
- [34]. Miyazono Y, Gao F, Horie T Oxidative stress contributes to methotrexate-induced small intestinal toxicity in rats.. *Scand J Gastroenterol.* 2004 Nov;39(11):1119-27
- [35]. El-Sheikh AA, Morsy MA, Hamouda AH. Protective Mechanisms of Thymoquinone on Methotrexate-induced Intestinal Toxicity in Rats. *Pharmacogn Mag.* 2016 Jan;12(Suppl):S76-81.
- [36]. Leitao RF, Brito GA, Oria RB, Braga-Neto MB, Bellaguarda EA, Silva JV, et al. Role of inducible nitric oxide synthase pathway on methotrexate-induced intestinal mucositis in rodents. *BMC Gastroenterol* 2011;11:90 [Epub 2011/08/19].

- [37]. Chang CJ, Lin JF, Chang HH, Lee GA, Hung CF Lutein protects against methotrexate-induced and reactive oxygen species-mediated apoptotic cell injury of IEC-6 cells. *PLoS One*. 2013 Sep 6;8(9):e72553. doi: 10.1371/journal.pone.0072553. eCollection 2013.
- [38]. Li T, Ito K, Sumi S, Fuwa T, Horie T. Protective effect of aged garlic extract (AGE) on the apoptosis of intestinal epithelial cells caused by methotrexate. *Cancer Chemother Pharmacol*. 2009 Apr;63(5):873-80. doi: 10.1007/s00280-008-0809-4. Epub 2008 Aug 2.
- [39]. Ramadan AA, Yousif WB, Ali AM. The effect of methotrexate (MTX) on the small intestine of the mouse. III. Mitochondria and succinic dehydrogenase (SDH). *Funct Dev Morphol*. 1992;2(1):3-9.
- [40]. Shaoul R, Moati D, Schwartz B, Pollak Y, Sukhotnik I. Effect of Pomegranate Juice on Intestinal Recovery Following Methotrexate-Induced Intestinal Damage in a Rat Model. *J Am Coll Nutr*. 2018;37(5):406-414.
- [41]. Toquet S, Nguyen Y, Sabbagh A, Djerada Z, Boulagnon C, Bani-Sadr F. Severe apoptotic enteropathy caused by methotrexate treatment for rheumatoid arthritis. *Joint Bone Spine*. 2016 ;83(2):217-9.
- [42]. Sukhotnik I, Geyer T, Pollak Y, Mogilner JG, Coran AG, Berkowitz D. The role of Wnt/ β -catenin signaling in enterocyte turnover during methotrexate-induced intestinal mucositis in a rat. *PLoS One*. 2014;9(11):e110675.
- [43]. Soldini D, Gaspert A, Montani M, Reineke T, Rogler G, Odze R, Weber A. Apoptotic enteropathy caused by antimetabolites and TNF- α antagonists. *J Clin Pathol*. 2014 ;67(7)
- [44]. Bateman E, Bowen J, Stringer A, Mayo B, Plews E, Wignall A, Greenberg N, Schiffrin E, Keefe D. Investigation of effect of nutritional drink on chemotherapy-induced mucosal injury and tumor growth in an established animal model. *Nutrients*. 2013 Sep 30;5(10)
- [45]. Sukhotnik I, Shteinberg D, Ben Lulu S, Bashenko Y, Mogilner JG, Ure BM, Shaoul R, Coran AG. Effect of transforming growth factor- α on enterocyte apoptosis is correlated with EGF receptor expression along the villus-crypt axis during methotrexate-induced intestinal mucositis in a rat. *Apoptosis*. 2008 Nov;13(11):1344-55.
- [46]. Gibson RJ, Bowen JM, Cummins AG, Keefe DM. Relationship between dose of methotrexate, apoptosis, p53/p21 expression and intestinal crypt proliferation in the rat. *Clin Exp Med*. 2005 Mar;4(4):188-95.
- [47]. Zhang H, Wang J, Lang W, Liu H, Zhang Z, Wu T, Li H, Bai L, Shi Q (2022) Alibiforin ameliorates inflammation and oxidative stress by regulating the NF- κ B/NLRP3 pathway in Methotrexate induced enteritis. *Int Immunopharmacol* 109:10882
- [48]. Şener G, Ekşioğlu-Demiralp E, Cetiner M, Ercan F, Şirvancı S, Gedik N, Yeğen B (2006) L-Carnitine ameliorates methotrexate induced oxidative organ injury and inhibits leukocyte death. *Cell Biol Toxicol* 22:47–60
- [49]. Kesik V, Uysal B, Kurt B, Kismet E, Koseoglu V (2009) Ozone ameliorates methotrexate-induced intestinal injury in rats. *Cancer Biol Ther* 8:1623–1628
- [50]. Miyazono Y, Gao F, Horie T (2004) Oxidative stress contributes to methotrexate-induced small intestinal toxicity in rats. *Scand J Gastroenterol* 39:1119–1127
- [51]. Hassanein EH, Ali FE, Sayed MM, Mahmoud AR, Jaber FA, Kotob MH, Abd-Elhamid TH (2023a) Umbelliferone potentiates intestinal protective effect of *Lactobacillus Acidophilus* against methotrexate-induced intestinal injury: biochemical and histological study. *Tissue Cell* 82:102103
- [52]. Sayed AM, Abdel-Fattah MM, Arab HH, Mohamed WR, Hassanein EH (2022) Targeting inflammation and redox aberrations by perindopril attenuates methotrexate-induced intestinal injury in rats: role of TLR4/NF- κ B and c-Fos/c-Jun pro-inflammatory pathways and PPAR- γ /SIRT1 cytoprotective signals. *Chemico-Biol Interact* 351:109732
- [53]. Drishya S, Dhanisha SS, Guruvayoorappan C (2022) Antioxidant-rich fraction of *Amomum subulatum* fruits mitigates experimental methotrexate-induced oxidative stress by regulating TNF- α , IL-1 β , and IL-6 proinflammatory cytokines. *J Food Biochem* 46:e13855
- [54]. Zorov DB, Juhaszova M, Sollott SJ (2006) Mitochondrial ROS-induced ROS release: an update and review. *Biochim et Biophys Acta (BBA)-Bioenergetics* 1757:509–517
- [55]. Pi D, Liu Y, Shi H, Li S, Odle J, Lin X, Zhu H, Chen F, Hou Y, Leng W (2014) Dietary supplementation of aspartate enhances intestinal integrity and energy status in weanling piglets after lipopolysaccharide challenge. *J Nutr Biochem* 25:456–462
- [56]. Trushina E, McMurray C (2007) Oxidative stress and mitochondrial dysfunction in neurodegenerative diseases. *Neuroscience* 145:1233–1248
- [57]. Kolli VK, Abraham P, Isaac B. Alteration in antioxidant defense mechanisms in the small intestines of methotrexate treated rat may contribute to its gastrointestinal toxicity. *Cancer therapy* 2007; 5B: 501-510
- [58]. Kolli VK, Abraham P, Rabi S. Methotrexate-induced nitrosative stress may play a critical role in small intestinal damage in the rat. *Arch Toxicol*. 2008 ; 82:763-70.
- [59]. Kolli V, Natarajan K, Isaac B, Selvakumar D, Abraham P. Mitochondrial dysfunction and respiratory chain defects in a rodent model of methotrexate-induced enteritis. *Hum Exp Toxicol*. 2014;33(10):1051-65.
- [60]. Natarajan K, Abraham P. Methotrexate administration induces differential and selective protein tyrosine nitration and cysteine nitrosylation in the subcellular organelles of the small intestinal mucosa of rats. *Chemico-biological interactions* 2016;251:45-59.
- [61]. Natarajan K, Abraham P, Isaac B. Effect of methotrexate treatment on iNOS gene expression, protein tyrosine nitration protein cysteine nitrosylation, and the activities of mitochondrial enzymes in the small intestinal mucosa of rats. *Asian Journal of Pharmacology and Toxicology* 2016;1: 2-6.
- [62]. Natarajan K, Abraham P, Kota R, Selvakumar D. Aminoguanidine pretreatment prevents methotrexate induced small intestinal injury in the rat by attenuating nitrosative stress and restoring the activities of vital mitochondrial enzymes. *J Basic Clin Physiol Pharmacol*. 2017 ;28:239-247
- [63]. Natarajan K, Abraham P, Kota R. Activation of the mitochondrial apoptotic pathway contributes to methotrexate-induced small intestinal injury in rats. *Cell Biochem Funct*. 2017 Oct;35(7):378-391. doi:10.1002/cbf.3285. Epub 2017 Sep 4.
- [64]. Natarajan K, Abraham P, Kota R, Isaac B. NF- κ B-iNOS-COX2-TNF α inflammatory signaling pathway plays an important role in methotrexate induced small intestinal injury in rats. *Food Chem Toxicol*. 2018 Aug;118:766-783
- [65]. Kobayashi A, Kang M-I, Okawa H, Ohtsuji M, Zenke Y, Chiba T, Igarashi K, Yamamoto M (2004) Oxidative stress sensor Keap1 functions as an adaptor for Cul3-based E3 ligase to regulate proteasomal degradation of Nrf2. *Mol Cell Biol* 24:7130–7139
- [66]. Wang X-J, Sun Z, Villeneuve NF, Zhang S, Zhao F, Li Y, Chen W, Yi X, Zheng W, Wondrak GT (2008) Nrf2 enhances resistance of cancer cells to chemotherapeutic drugs, the dark side of Nrf2. *Carcinogenesis* 29:1235–1243
- [67]. Katturajan R, Evan Prince S (2023) Zinc and L-carnitine combination with or without methotrexate prevents intestinal toxicity during arthritis treatment via Nrf2/Sirt1/Foxo3 pathways: an in vivo and molecular docking approach. *Inflammopharmacology* 31:2599–2614
- [68]. Al-Kofahi M, Yun JW, Minagar A, Alexander JS (2017) Anatomy and roles of lymphatics in inflammatory diseases. *Clin Experimental Neuroimmunol* 8:199–214
- [69]. Liu T, Zhang L, Joo D, Sun S-C (2017a) NF- κ B signaling in inflammation. *Signal Transduct Target Therapy* 2:1–9
- [70]. Li Q, Verma IM (2002) NF- κ B regulation in the immune system. *Nat Rev Immunol* 2:725–734

- [71]. Logan RM, Stringer AM, Bowen JM, Yeoh ASJ, Gibson RJ, Sonis ST, et al. . The role of proinflammatory cytokines in cancer treatment-induced alimentary tract mucositis: pathobiology, animal models and cytotoxic drugs. *Cancer Treat Rev* 2007;33(5):448–60. doi: 10.1016/j.ctrv.2007.03.001
- [72]. Hamada K, Kakigawa N, Sekine S, Shitara Y, Horie T. Disruption of ZO-1/claudin-4 interaction in relation to inflammatory responses in methotrexate-induced intestinal mucositis. *Cancer Chemother Pharmacol* 2013;72(4):757–65.
- [73]. Huang G, Yuan M, Zhang J, Li J, Gong D, Li Y, Lin P, Huang L (2016) IL-6 mediates differentiation disorder during spermatogenesis in obesity-associated inflammation by affecting the expression of Zfp637 through the SOCS3/STAT3 pathway. *Sci Rep* 6:1–11
- [74]. Zhu L, Gu P, Shen H (2019) Protective effects of berberine hydrochloride on DSS-induced ulcerative colitis in rats. *Int Immunopharmacol* 68:242–251
- [75]. Cha B, Lim JW, Kim H (2015) Jak1/Stat3 is an upstream signaling of NF- κ B activation in Helicobacter pylori-induced IL-8 production in gastric epithelial AGS cells. *Yonsei Med J* 56:862–866
- [76]. Lin Y-C, Lin C-K, Tsai Y-H, Weng H-H, Li Y-C, You L, Chen J-K, Jablons DM, Yang C-T (2010) Adenovirus-mediated SOCS3 gene transfer inhibits the growth and enhances the radiosensitivity of human non-small cell lung cancer cells. *Oncol Rep* 24:1605–1612
- [77]. de Araujo Junior RF, da Silva Reinaldo MPO, de Castro Brito GA, de Cavalcanti Franca P, de Moura Freire MA, de Medeiros CAX, de Araujo AA (2014) Olmesartan decreased levels of IL-1 β and TNF- α , down-regulated MMP-2, MMP-9, COX-2, RANK/ RANKL and up-regulated SOCS-1 in an intestinal mucositis model. *PLoS One* 10(3):e0120057
- [78]. Wang S, Dougherty EJ, Danner RL (2016) PPAR γ signaling and emerging opportunities for improved therapeutics. *Pharmacol Res* 111:76–85
- [79]. Ricote M, Huang JT, Welch JS, Glass CK (1999) The peroxisome proliferator-activated receptor γ (PPAR γ) as a regulator of monocyte/macrophage function. *J Leukoc Biol* 66:733–739
- [80]. Sayed AM, Abdel-Fattah MM, Arab HH, Mohamed WR, Hassanein EH (2022) Targeting inflammation and redox aberrations by perindopril attenuates methotrexate-induced intestinal injury in rats: role of TLR4/NF- κ B and c-Fos/c-Jun pro-inflammatory pathways and PPAR- γ /SIRT1 cytoprotective signals. *Chemico-Biol Interact* 351:109732
- [81]. Mansoury M, Almukadi H, Turkistani AM, Khatib HA, Ali SS, Hassanein EH, Alahmadi BA, Al-Jaouni S, El-Shitany NA (2023) Apocynin attenuates methotrexate-induced mucositis by regulating NF- κ B, PPAR- γ and Bax/Bcl-2/Puma signals. *Pak J Pharm Sci* 36(2):457–466
- [82]. Hafez HM, Ibrahim MA, Ibrahim SA, Amin EF, Goma W and Abdelrahman AM: Potential protective effect of etanercept and aminoguanidine in methotrexate-induced hepatotoxicity and nephrotoxicity in rats. *Eur J Pharmacol.* 768:1–12. 2015
- [83]. Leitão RF, Brito GA, Oriá RB, Braga-Neto MB, Bellaguarda EA, Silva JV, Gomes AS, Lima-Júnior RC, Siqueira FJ, Freire RS, Vale ML, Ribeiro RA. Role of inducible nitric oxide synthase pathway on methotrexate-induced intestinal mucositis in rodents. *BMC Gastroenterol.* 2011 Aug 16;11:90. doi: 10.1186/1471-230X-11-90
- [84]. Amaral, F. G. D. & Cipolla-Neto, J. A brief review about melatonin, a pineal hormone. *Arch. Endocrinol. Metab.* 62, 472–479 (2018).
- [85]. Tan, D. X., Manchester, L. C., Esteban-Zubero, E., Zhou, Z. & Reiter, R. J. Melatonin as a potent and inducible endogenous antioxidant: synthesis and metabolism. *Molecules* 20, 18886–18906 (2015).
- [86]. Martinez, G. R. et al. Measurement of melatonin and its metabolites: importance for the evaluation of their biological roles. *Endocrine* 27, 111–118 (2005).
- [87]. Kolli VK, Abraham P, Isaac B, Kasthuri N Preclinical efficacy of melatonin to reduce methotrexate-induced oxidative stress and small intestinal damage in rats. *Dig Dis Sci.* 2013 Apr;58(4):959-69. doi: 10.1007/s10620-012-2437-4.
- [88]. Kolli VK, Kanakasabapathy I, Faith M, Ramamoorthy H, Isaac B, Natarajan K, Abraham P. A preclinical study on the protective effect of melatonin against methotrexate-induced small intestinal damage: effect mediated by attenuation of nitrosative stress, protein tyrosine nitration, and PARP activation. *Cancer Chemother Pharmacol.* 2013 May;71(5):1209-18
- [89]. Çelik H, Kandemir FM, Caglayan C, Özdemir S, Çomaklı S, Kucukler S, Yardım A (2020) Neuroprotective effect of rutin against colistin-induced oxidative stress, inflammation and apoptosis in rat brain associated with the CREB/BDNF expressions. *Mol Biol Rep* 47:2023–2034
- [90]. Caglayan C, Kandemir FM, Yildirim S, Kucukler S, Eser G (2019) Rutin protects mercuric chloride-induced nephrotoxicity via targeting of aquaporin 1 level, oxidative stress, apoptosis and inflammation in rats. *J Trace Elem Med Biol* 54:69–78
- [91]. Kandemir FM, Caglayan C, Aksu EH, Yildirim S, Kucukler S, Gur C, Eser G (2020) Protective effect of rutin on mercuric chloride-induced reproductive damage in male rats. *Andrologia* 52:e13524
- [92]. Gautam R, Singh M, Gautam S, Rawat JK, Saraf SA, Kaithwas G (2016) Rutin attenuates intestinal toxicity induced by Methotrexate linked with anti-oxidative and anti-inflammatory effects. *BMC Complement Altern Med* 16:1–6
- [93]. Semis HS, Kandemir FM, Kaynar O, Dogan T, Arıkan SM (2021) The protective effects of hesperidin against paclitaxel-induced peripheral neuropathy in rats. *Life Sci* 287:120104
- [94]. Yurtal Z, Altug ME, Unsaldi E, Secinti IE, Kucukgul A (2020) Investigation of neuroprotective and therapeutic effects of Hesperidin in experimental spinal cord injury. *Turkish Neurosurg* 30:899–90
- [95]. Patel P, Shah J (2021) Protective effects of hesperidin through attenuation of Ki67 expression against DMBA-induced breast cancer in female rats. *Life Sci* 285:119957
- [96]. Çetin A, Çiftçi O, Otlı A (2016) Protective effect of hesperidin on oxidative and histological liver damage following carbon tetrachloride administration in Wistar rats. *Archives Med Sci* 12:486–493
- [97]. Sheikhabaee F, Khazaei M, Rabzia A, Mansouri K, Ghanbari A (2016) Protective effects of thymoquinone against methotrexate-induced germ cell apoptosis in male mice. *Int J Fertility Steril* 9:541
- [98]. El AE-DE-S, Sokar SS, Shebl AM, Mohamed DZ (2017) Antifibrotic effect of diethylcarbamazine combined with hesperidin against ethanol induced liver fibrosis in rats. *Biomed Pharmacother* 89:1196–1206
- [99]. Acipayam C, Bayram I, Daglioglu K, Doran F, Yılmaz S, Sezgin G, Totan Ateş B, Ozkan A, Tanyeli A (2013) The protective effect of hesperidin on methotrexate-induced intestinal epithelial damage in rats: an experimental study. *Med Principles Pract* 23:45–52
- [100]. Abdel-Daim MM, Eissa IA, Abdeen A, Abdel-Latif HM, Ismail M, Dawood MA, Hassan AM (2019) Lycopene and resveratrol ameliorate zinc oxide nanoparticles-induced oxidative stress in Nile tilapia, Oreochromis niloticus. *Environ Toxicol Pharmacol* 69:44–50
- [101]. Ibrahim IM, Althagafy HS, Abd-Alhameed EK, Al-Thubiani WS, Hassanein EHM (2022) Promising hepatoprotective effects of lycopene in different liver diseases. *Life Sci* 310:1211
- [102]. Müller L, Fröhlich K, Böhm V (2011) Comparative antioxidant activities of carotenoids measured by ferric reducing antioxidant power Naunyn-Schmiedeberg's Archives of Pharmacology (FRAP), ABTS bleaching assay (α TEAC), DPPH assay and peroxyl radical scavenging assay. *Food Chem* 129:139–148
- [103]. Yucel Y, Tabur S, Gozeneli O, Kocarslan S, Seker A, Buyukaslan H, Şavik E, Aktumen A, Ozgonul A, Uzunkoy A (2016) The effects of lycopene on intestinal injury due to methotrexate in rats. *Redox Rep* 21:113–118

- [104]. Mao T, Han C, Wei B, Zhao L, Zhang Q, Deng R, Liu J, Luo Y, Zhang Y (2018) Protective effects of quercetin against cadmium chloride-induced oxidative injury in goat sperm and zygotes. *Biol Trace Elem Res* 185:344–355
- [105]. Sukhotnik I, Moati D, Shaoul R, Loberman B, Pollak Y, Schwartz B (2018) Quercetin prevents small intestinal damage and enhances intestinal recovery during methotrexate-induced intestinal mucositis of rats. *Food Nutr Res* 62:1327
- [106]. Nwokocha CR, Palacios J, Rattray VR, McCalla G, Nwokocha M, McGrowder D (2020) Protective effects of apocynin against cadmium toxicity and serum parameters; evidence of a cardioprotective influence. *Inorg Chim Acta* 503:1194
- [107]. Mansoury M, Almukadi H, Turkistani AM, Khattab HA, Ali SS, Hassanein EH, Alahmadi BA, Al-Jaouni S, El-Shitany NA (2023) Apocynin attenuates methotrexate-induced mucositis by regulating NF- κ B, PPAR- γ and Bax/Bcl-2/Puma signals. *Pak J Pharm Sci* 36(2):457–466
- [108]. Hassanein EH, Althagafy HS, Atwa AM, Kozman MR, El-Sayed MIK, Soubh AA (2022) Taurine attenuated methotrexate-induced intestinal injury by regulating NF- κ B/iNOS and Keap1/Nrf2/ HO-1 signals. *Life Sci* 311:121180
- [109]. Oscarsson J, Hurt-Camejo E (2017) Omega-3 fatty acids eicosapentaenoic acid and docosahexaenoic acid and their mechanisms of action on apolipoprotein B-containing lipoproteins in humans: a review. *Lipids Health Dis* 16:1–13
- [110]. Karageorgou D, Rova U, Christakopoulos P, Katapodis P, Matsakas L, Patel A (2023) Benefits of supplementation with microbial omega-3 fatty acids on human health and the current market scenario for fish-free omega-3 fatty acid. *Trends in Food Science & Technology*
- [111]. Koppelman T, Pollak Y, Ben-Shahar Y, Gorelik G, Sukhotnik I (2021) The mechanisms of the anti-inflammatory and anti-apoptotic effects of omega-3 polyunsaturated fatty acids during methotrexate-induced intestinal damage in cell line and in a rat model. *Nutrients* 13:888
- [112]. Mazimba O (2017) Umbelliferone: sources, chemistry and bioactivities review. *Bull Fac Pharm Cairo Univ* 55:223–232
- [113]. Navarro-García VM, Rojas G, Avilés M, Fuentes M, Zepeda G (2011) In vitro antifungal activity of coumarin extracted from *Loeselia mexicana* Brand. *Mycoses* 54:e569–e571
- [114]. Hoult J, Payá M (1996) Pharmacological and biochemical actions of simple coumarins: natural products with therapeutic potential. *Gen Pharmacology: Vascular Syst* 27:713–722
- [115]. Cruz LF, de Figueiredo GF, Pedro LP, Amorim YM, Andrade JT, Passos TF, Rodrigues FF, Souza ILA, Gonçalves TPR, dos Santos Lima LAR (2020) Umbelliferone (7-hydroxycoumarin): a non-toxic antidiarrheal and antiulcerogenic coumarin. *Biomed Pharmacother* 129:110432
- [116]. Lopez-Gonzalez JS, Prado-Garcia H, Aguilar-Cazares D, MolinaGuarneros JA, Morales-Fuentes J, Mandoki JJ (2004) Apoptosis and cell cycle disturbances induced by coumarin and 7-hydroxycoumarin on human lung carcinoma cell lines. *Lung Cancer* 43:275–283
- [117]. Vardi N, Parlakpınar H, Ozturk F, Ates B, Gul M, Cetin A, Erdogan A, Otlu A Potent protective effect of apricot and beta-carotene on methotrexate-induced intestinal oxidative damage in rats. *Food Chem Toxicol.* 2008 Sep;46(9):3015-22.
- [118]. Koppelman T, Pollak Y, Mogilner J, Bejar J, Coran AG, Sukhotnik I. Dietary L-arginine supplementation reduces Methotrexate-induced intestinal mucosal injury in rat. *BMC Gastroenterol.* 2012Apr 30;12:41. doi: 10.1186/1471-230X-12-4
- [119]. Burcu B, Kanter M, Orhon ZN, Yarali O, .Protective Effects of Vitamin E on Methotrexate-Induced Jejunal Mucosal Damage in Rats. *Anal Quant Cytopathol Histopathol.* 2016 ;38(2):87-94.
- [120]. Akbulut S, Elbe H, Eris C, Dogan Z, Toprak G, Otan E, et al. . Cytoprotective effects of amifostine, ascorbic acid and N-acetylcysteine against methotrexate-induced hepatotoxicity in rats. *World J Gastroenterol* 2014;20(29):10158.
- [121]. Yüncü M, Eralp A, Koruk M, Sari I, Bağcı C, Inalöz S. Effect of vitamin A against methotrexate induced damage to the small intestine in rats. *Med Princ Pract* 2004;13(6):346–52.